Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer.

[Display omitted] • Diagnosing asbestos-related lung cancer (ARLC) is challenging. • Circulating tumor cells (CTCs) are a promising liquid biopsy biomarker. • CTCs could improve screening high-risk populations including those exposed to asbestos. • CTCs could provide molecular insights into ARLC, improving diagnosis and patient management. Asbestos-Related Lung Cancer (ARLC) presents ongoing diagnostic challenges despite improved imaging technologies. The long latency period, coupled with limited access to occupational and environmental data along with the confounding effects of smoking and other carcinogens adds complexity to the diagnostic process. Compounding these challenges is the absence of a specific histopathologic or mutational signature of ARLC. A correlation between PD-L1 expression and response to immune checkpoint inhibition has not yet been proven. Thus, new biomarkers are needed to allow accurate diagnoses of ARLC, to enable prognostication and to offer personalized treatments. Liquid biopsies, encompassing circulating DNA and circulating tumor cells (CTCs), have gained attention as novel diagnostic methods in lung cancer to screen high-risk populations including those exposed to asbestos. CTCs can be enumerated and molecularly profiled to provide predictive and prognostic information. CTC studies have not been undertaken in populations at risk of ARLC to date. The potential of CTCs to provide real-time molecular insight into ARLC biology may significantly improve the diagnosis and management of ARLC patients. [ABSTRACT FROM AUTHOR]